Sensus Healthcare (SRTS) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
7 May, 2026Executive summary
Transitioned to a new reimbursement environment with dedicated CPT codes for superficial radiotherapy effective January 1, 2026, fundamentally changing business dynamics and improving reimbursement clarity.
Focused on five strategic priorities: market education, customer adoption, recurring revenue growth, commercial model diversification, and sustainable profitability.
Saw increased customer inquiries, pipeline growth, and broader engagement from dermatology practices and hospital systems.
Shipped 14 SRT systems in Q1 2026 (10 direct, 4 under Fair Deal/rental), matching Q4 shipments but down from 30 in Q1 2025; none of the direct sales were to the largest customer.
Ended the quarter with $18.3 million in cash and no debt.
Financial highlights
Q1 2026 revenue was $3.4 million, down from $8.3 million in Q1 2025, mainly due to no sales to the historically largest customer and fewer units shipped.
Excluding sales to the largest customer, revenue increased from $2.7 million to $3.4 million, reflecting underlying growth and diversification.
Gross profit was $1 million (29.2% margin) versus $4.4 million (52.2% margin) in Q1 2025, with margin decline driven by product mix, more Fair Deal placements, and higher international shipments.
Adjusted EBITDA was negative $4.2 million, compared to negative $2.5 million in Q1 2025.
Net loss was $2.6 million or $0.16 per share, unchanged from the prior year.
Outlook and guidance
Q2 2026 revenue expected to be higher than Q1, with second half revenue projected to exceed the first half as pipeline momentum builds.
Profitability targeted for full-year 2026, with each quarter expected to improve sequentially.
Revenue from recurring streams, including FDA, service, and software, anticipated to represent a growing share of total revenue.
Management is focused on education, accelerating adoption, expanding recurring revenue, broadening commercial reach, and driving toward profitability in 2026.
New CPT Codes are expected to improve sales pipeline quality, customer engagement, and decision-making speed.
Latest events from Sensus Healthcare
- Proxy seeks votes on directors, executive pay, and auditor, with robust governance and risk oversight.SRTS
Proxy filing29 Apr 2026 - Reimbursement clarity and strong cash reserves set the stage for profitability in 2026.SRTS
Q4 202512 Feb 2026 - Q2 revenue rose 104% to $9.2M, with strong SRT sales and new recurring revenue model launched.SRTS
Q2 20242 Feb 2026 - Q3 revenue jumped 127% year-over-year, with future growth tied to major recurring agreements.SRTS
Q3 202414 Jan 2026 - Record revenue and shipments in 2024 set the stage for recurring growth via Fair Deal Agreements.SRTS
Q4 20242 Dec 2025 - Shareholders will vote on director election, incentive plan amendment, executive pay, and auditor ratification.SRTS
Proxy Filing1 Dec 2025 - Q1 2025 saw lower revenue and a net loss, but profitability is forecasted for the year.SRTS
Q1 202525 Nov 2025 - Q2 revenue and profit declined, but recurring revenue and FDA treatment volume increased.SRTS
Q2 202524 Nov 2025 - Q3 2025 revenue and profit fell, but new CMS codes and strong cash support future growth.SRTS
Q3 202515 Nov 2025